Answers are grounded in this paper and cite their sources.
Postcholecystectomy diarrhea (PCD) is a gastrointestinal complication following gallbladder removal that may adversely affect patients’ quality of life. Bifidobacterium triple viable capsules are used as adjunctive therapy to regulate intestinal microbiota and potentially improve gastrointestinal symptoms. This systematic review and meta-analysis aims to evaluate the efficacy and safety of adding Bifidobacterium triple viable capsules to background treatment, compared with the same background treatment without these capsules, in patients with established PCD. Randomized controlled trials will be identified through searches of international and Chinese bibliographic databases. Outcomes of interest include clinical treatment response, stool-related measures, intestinal microbiota, D-lactate, secretory immunoglobulin A, recurrence, and adverse events, where reported. Risk of bias will be assessed using the Cochrane RoB 2 tool, and quantitative synthesis will be conducted where appropriate. This registration is retrospective: preliminary study selection, data extraction for six candidate randomized trials, and initial risk-of-bias assessments have already been undertaken. Database searches and eligibility verification are ongoing, and quantitative meta-analysis has not yet commenced.
No takes yet. Share an insight, caveat, or question.
LYM0301 (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: